CIK 0001158780
- Non-accelerated filer
- Smaller reporting company
Pluri Inc.
Sign in to watch- Ticker
- PLUR
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Jun 30
- Incorporated
- NV
- Entity type
- Operating
- EIN
- 980351734
- Phone
- +972 747107171
- Business address
- MATAM ADVANCED TECHNOLOGY PARK, BUILDING NO. 5, HAIFA, Israel
- Former names
- PLURISTEM THERAPEUTICS INC, PLURISTEM LIFE SYSTEMS INC, AI SOFTWARE INC
- 4 Open-market buy Director bought 12,346 shares at $0.81 ($9,968)
- 4 Open-market buy Director bought 10,000 shares at $0.79 ($7,900)
- 4 Open-market buy CFO, COO & President bought 5,000 shares at $0.83 ($4,139)
- 4 Open-market buy CEO & Chairman bought 31,000 shares at $0.80 ($24,716)
- 4 Grant or award Director acquired 49,000 shares (grant or award)
- 4 Grant or award CEO & Chairman acquired 150,000 shares (grant or award)
- 4 Grant or award CFO, COO & President acquired 150,000 shares (grant or award)
- 4 Grant or award Director acquired 49,000 shares (grant or award)
- 4 Grant or award Director acquired 35,000 shares (grant or award)
- 4 Grant or award Director acquired 48,000 shares (grant or award)
- 4 Grant or award Director acquired 35,000 shares (grant or award)
- 4 Grant or award Director acquired 35,000 shares (grant or award)
- 4 Grant or award Director acquired 49,000 shares (grant or award)
- 4 Open-market buy CEO & Chairman bought 9,900 shares at $1.49 ($14,751)
- 4 Open-market buy CFO, COO & President bought 10,000 shares at $1.52 ($15,200)
- 4 Open-market sale Director sold 30,000 shares at $2.10 ($63,000)
- 4 Open-market buy CFO, COO & President bought 10,000 shares at $2.11 ($21,100)
- 4 Open-market buy CEO & Chairman bought 25,500 shares at an average $2.11 ($53,780)
- 4 Open-market buy COO, CFO & President bought 10,000 shares at an average $2.12 ($21,155)
- 4 Open-market buy CEO & Chairman bought 25,000 shares at an average $2.11 ($52,750)
Page 7 of 18 · 352 filings